Massive thrombosis of brachiocephalic veins and superior vena cava syndrome in a patient with non-small cell lung cancer treated with the epidermal growth factor receptor inhibitor erlotinib

Clinical Drug Investigation

Volumn 27, Issue 7, 2007, Pages 499-503

  Salmi, Raffaella ^a   Gaudenzi, Piergiorgio ^a   Di Todaro, Filippo ^a   Morandi, Pierluigi ^a   Nielsen, Ingrid ^a   Manfredini, Roberto ^a,b  

^a S ANNA HOSPITAL   (Italy)

^b UNIVERSITY OF FERRARA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BEMIPARIN; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FIBRINOLYTIC AGENT; FUROSEMIDE; GEFITINIB; GEMCITABINE; HYDROCORTISONE; UROKINASE;

ADULT; ARTICLE; BLEEDING; BRACHIOCEPHALIC VEIN; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CYANOSIS; DRUG WITHDRAWAL; DYSPNEA; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; SUPERIOR CAVA VEIN SYNDROME; SYNCOPE; THORACOCENTESIS; THORAX; VEIN THROMBOSIS;

ANTINEOPLASTIC AGENTS; BRACHIOCEPHALIC VEINS; CARCINOMA, NON-SMALL-CELL LUNG; CYANOSIS; FEMALE; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SUPERIOR VENA CAVA SYNDROME; SYNCOPE; TOMOGRAPHY, X-RAY COMPUTED; VENOUS THROMBOSIS;

EID: 34250315334     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200727070-00007     Document Type: Article

References (26)

1. Ono M, Kuwano M. Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs. Clin Cancer Res 2006; 12: 7242-51
2. Brabender J, Danenberg KJ, Metzger R, et al. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin Cancer Res 2001; 7: 1850-5
3. Sridhar SS, Seymour L, Shepherd FA. Inhibitors of epidermal-growth-factor receptors: a review of clinical studies with a focus on non-small cell lung cancer. Lancet Oncol 2003; 4: 397-406
4. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updat-ed data on individual patients from 52 randomised clinical studies. BMJ 1995; 311: 899-909
5. Shepherd FA, Pereira JR, Ciuleanu T, et al. Erlotinib in previously treated non-small cell lung cancer. N Engl J Med 2005; 353: 123-32
6. Esposito D. Emergency complications of malignancy. In: Tintinalli JE, Krome RL, Ruiz E, editors. Emergency medicine. 3rd ed. New York: McGraw-Hill, Inc., 1992: 780-1
7. Antman K, Marks AR. The patient with cardiovascular disease and cancer. In: Zipes DP, Libby P, Bonow RO, et al., editors. Braunwald's heart disease. Philadelphia (PA): Elsevier Saunders, 2005: 2117-28
8. Wudel Jr LJ, Nesbitt C. Superior vena cava syndrome. Curr Treat Options Oncol 2001; 2: 77-91
9. Baker GL, Barnes HJ. Superior vena cava syndrome: etiology, diagnosis, and treatment. Am J Crit Care 1992; 1: 54-64
10. Unver S, Atasoyu EM, Evrenkaya TR, et al. Vena cava superior syndrome developing in a dialysis patient with antithrombin III deficiency following temporary catheterization. Clin Nephrol 2006; 65: 71-4
11. Tan CW, Vijitenjaronk P, Khuri B. Superior vena cava syndrome due to permanent transvenous pacemaker electrodes: successful treatment with combined thrombolysis and angioplasty: a case report. Angiology 2000; 51: 963-9
12. Castelli P, Caronno R, Piffaretti G, et al. Endovascular treatment for superior vena cava obstruction in Behcet disease. J Vasc Surg 2005; 41: 548-51
13. Higdon MI, Higdon JA. Treatment of oncologic emergencies. Am Fam Physician 2006; 74: 1873-80
14. Yim CD, Sane SS, Bjarnason H. Superior vena cava stenting. Radiol Clin North Am 2000; 38: 409-24
15. Thony F, Moro D, Witmeyer P, et al. Endovascular treatment of superior vena cava obstruction in patients with malignancies. Eur Radiol 1999; 9: 965-71
16. Agero AL, Dusza SW, Benvenuto-Andrade C, et al. Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol 2006; 55: 657-70
17. Sandler AB. Nondermatologic adverse events associated with anti-EGFR therapy. Oncology (Williston Park) 2006; 20 (5 Suppl. 2): 35-40
18. Lenz HJ. Anti-EGFR mechanism of action: antitumor effect and underlying cause of adverse events. Oncology (Williston Park) 2006; 20 (5 Suppl. 2): 5-13
19. Verheul HM, Pinedo HM. Inhibition of angiogenesis in cancer patients. Expert Opin Emerg Drugs 2005; 10: 403-12
20. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239-45
21. Bick RL. Cancer-associated thrombosis. N Engl J Med 2003; 349: 109-11
22. Levitan N, Dowlati A, Remick SC, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy: risk analysis using Medicare claims data. Medicine (Baltimore) 1999; 78: 285-91
23. Carson JL, Kelley MA, Duff A, et al. The clinical course of pulmonary embolism. N Engl J Med 1992; 326: 1240-5
24. Manfredini R, Boari B, Gallerani M, et al. Acute multiple thrombosis as early presentation of lung cancer. Ann Emerg Med 2004; 44: 89-90
25. Emmerich J, Meyer G, Decousus H, et al. Role of fibrinolysis and interventional therapy for acute venous thromboembolism. Thromb Haemost 2006; 96: 251-7
26. Gray BH, Olin JW, Graor RA, et al. Safety and efficacy of thrombolytic therapy for superior vena cava syndrome. Chest 1991; 99: 54-9